Jpmorgan Chase & CO E Ffector Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.37 - $0.69 $14 - $26	38 Added 126.67%	68 $0
Q3 2023 Nov 14, 2023	BUY	$0.49 - $0.88 $14 - $26	30 New	30 $0
Q1 2022 May 11, 2022	SELL	$3.85 - $8.2 $3,003 - $6,395	-780 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$5.71 - $13.15 $4,453 - $10,257	780 New	780 $6,000

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.